Halozyme Therapeutics (NASDAQ:HALO) Releases FY 2025 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 4.950-5.350 for the period, compared to the consensus estimate of 4.690. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Halozyme Therapeutics also updated its FY 2024 guidance to 4.000-4.200 EPS.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $51.19 on Wednesday. The firm has a fifty day moving average of $50.10 and a 200-day moving average of $54.00. Halozyme Therapeutics has a 52-week low of $33.15 and a 52-week high of $65.53. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The firm has a market capitalization of $6.51 billion, a P/E ratio of 16.95, a PEG ratio of 0.44 and a beta of 1.24.

Analyst Ratings Changes

A number of research analysts have commented on the company. Piper Sandler boosted their price objective on Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a research note on Monday, November 4th. HC Wainwright reissued a “buy” rating and set a $68.00 price target on shares of Halozyme Therapeutics in a research report on Monday, December 30th. JMP Securities increased their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Wells Fargo & Company lowered shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price objective for the company from $58.00 to $62.00 in a research note on Monday, October 7th. Finally, Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $61.11.

Insider Buying and Selling

In related news, Director Jeffrey William Henderson sold 10,000 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the transaction, the director now directly owns 43,611 shares in the company, valued at $2,180,986.11. This trade represents a 18.65 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 2.70% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.